Back

Bismuth subsalicylate profoundly alters gut microbiome and immunity with increased susceptibility to infection

Band, V. I.; Lapoint, P.; Levy, S.; Krausfeldt, L.; Lacroix, I. S.; Chong, A.; Brandes, N. T.; Schwarz, B.; Mistry, S.; Burns, A. S.; Bacorn, M.; Banks, K.; Strength, R.; Chen, Q.; Romero-Soto, H. N.; Prasad, R.; Apps, R.; Wang, L.; Douagi, I.; Polanco, J. J.; Kotekar, A.; Mukherjee, A.; Koroleva, G.; Compean, A.; Sellers, B.; Langowski, T.; Rose, K.; Roy, S.; Namasivayam, S.; Perez-Chaparro, P. J.; Chau, J.; Stacy, A.; Belkaid, Y.; Hourigan, S. K.

2025-10-03 gastroenterology
10.1101/2025.10.01.25337000 medRxiv
Show abstract

Bismuth subsalicylate (BSS) is a commonly used over-the-counter medication for a variety of gastrointestinal symptoms. BSS sequesters gut sulfides, which have been shown in murine studies to be key regulators of gut microbiota. Here, we investigated the impact of BSS on human gut microbiome, immunity and susceptibility to enteric pathogens. We observed a significant shift in microbiome composition after BSS usage, with a profound expansion in bacteria with pathogenic potential including Pseudomonadota. Metabolite composition was greatly altered with increased amino acid levels and decreased short chain fatty acids and secondary bile acids. Notably, there was a collapse of key CD4 T cell subsets in the ileum. Finally, mouse and ex vivo human models revealed that BSS treatment increases susceptibility to colonization with the enteric pathogen Salmonella enterica. This study underlines the key role of sulfides in human gut microbiome and immunity and warrants further investigation into commonly used sulfide-depleting drugs.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.